Past HSG Research Trials & Studies

Past HSG Research Studies and Clinical Trials

HSG is the world leader in conducting clinical studies in Huntington disease. Below are some of the more recent past studies run by the HSG.

If you are interested in taking part in a current HSG study, please visit the Current HSG Studies web page, or contact the HSG directly via phone (800) 487-7671 (toll free from the U.S. and Canada) or email (info@hsglimited.org) for more information. If you would prefer to have the HSG reach you directly about new research opportunities, please sign up to be contacted about future clinical trials and observational studies here.

SIGNAL300_79

 Enrollment complete.

A Phase II research trial for people who are at risk for Huntington Disease (HD) and have early signs of HD. The study will assess the safety, tolerability, and effectiveness of VX15 (a novel monoclonal antibody).

 Learn more about SIGNAL

  Contact me about future HSG trials

LEGATOHDlogoRGB

 Enrollment complete.

A multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of laquininmod as treatment in patients with Huntington’s Disease.

 Learn more about LEGATO-HD

 Contact me about future HSG trials

pride300x79

 Enrollment complete.

A randomized, double blind Phase II research study of the effects of pridopidine in patients with Huntington disease.

 Learn more about Pride-HD

 Contact me about future HSG trials

300x79

 Enrollment complete.

A Randomized, Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea associated with Huntington Disease.

 Learn more about First-HD

 Contact me about future HSG trials

arc300x79

 Enrollment complete.

A Randomized, Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea associated with Huntington Disease for those currently taking tetrabenazine to treat chorea and “switch” to SD-809 ER.

 Learn more about ARC-HD

 Contact me about future HSG trials

crest300x79

 Enrollment complete.

Creatine Safety, Tolerability, and Efficacy in Huntington’s disease.

 Learn more about CREST-E

 Contact me about future HSG trials

2care300x79

 Enrollment complete.

Coenzyme Q10 (CoQ) in Huntington’s Disease.

 Learn more about 2CARE

 Contact me about future HSG trials

prequel300x79

 In publication.

A Multi-Center, Tolerability Study of Coenzyme Q10 (UbiquinonE) in PREmanifest Huntington’s disease.

 Read publications

 Contact me about future HSG trials

reach2hd300x79

 In publication.

A Multi-Center, Phase II Safety and Tolerability Trial of PBT2 in Patients with Early to Mid-stage HD.

 Read publications

 Contact me about future HSG trials

HART300x79

 In publication.

A Multi-Center, Study Comparing Three Doses Of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease.

 Read publications

 Contact me about future HSG trials


predicthd300x79

 Enrollment complete.

Observational Study of Neurobiological Predictors of Huntington’s Disease.

 Read publications

 Contact me about future HSG trials

For more information visit clinicaltrials.gov and hdtrialfinder.org